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Background: Sustained intratumoral cytokine release using poly-lactic acid micro-
spheres (PLAMs) can induce a systemic immune response, shifting immunotherapy to
the neoadjuvant setting.
Methods: C57BL6 mice with established B16 melanomas underwent a single
intralesional injection of IL-12, TNF-a or GM-CSF PLAM, alone or in combination.
Tumor draining lymph nodes (TDLN) and spleens were assessed for a specific anti-
tumor response by IFNg release assay and ELISPOT.
Results: Intralesional injection of TNF-a, alone or in combination, resulted in
significant tumor ablation. The induction of tumor specific reactive T-cells in the
TDLN was greatest with IL-12 and TNF-a. Only mice treated with IL-12 and TNF-a
demonstrated a substantial T-cell response in cultured splenocytes. This combination
resulted in a significant reduction in new tumors after re-challenge. Adjuvant therapy,
using irradiated B16 cells in combination with equivalent doses of IL-12 and TNF-a,
failed to generate a similar T-cell response or prevent re-challenge.
Conclusions: Intratumoral IL-12 and TNF-a loaded PLAM leads to both local
eradication of tumor and the induction of specific anti-tumor T-cells in the lymph
nodes and spleens, resulting in memory immune response. Neoadjuvant treatment was
significantly superior to postoperative autologous cellular vaccines using IL-12 and
TNF-a PLAM.
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INTRODUCTION
Activation of the immune system to produce an anti-
tumor response depends on the presentation of antigen to
T-cells by antigen presenting cells (APC) and the
production of cytokines that promote a Th1 cytotoxic
response. Various formulations of vaccines designed to
activate a Th1 response using cytokines as adjuvant
immunostimulants are presently being studied. These
include the use of either dendritic cells exogenously
loaded with tumor-associated antigens or autologous
tumor cells that have been transfected with genes
encoding immunostimulatory cytokines and then deliv-
ered as a postoperative vaccine. Multiple cytokines have
been investigated for this purpose with varying levels of
success.
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Autologous cellular vaccines and dendritic cell
vaccines are limited in both the amount of antigenic
material that can be used and the levels and duration of
cytokine release. An alternate approach is the sustained
release of cytokines directly into tumors to provide not
only local control, but also to stimulate a systemic
immune response. This would shift the immunotherapy
from an adjuvant setting to a neoadjuvant setting. We
have recently described a novel method for delivering a
local and sustained release of cytokines to the tumor
microenvironment that does not require genetic manip-
ulation [1]. Utilizing the B16 (murine melanoma) model,
we sought to investigate the use of cytokine-loaded poly-
lactic acid microspheres (PLAMs) as intralesional
therapy for melanoma, to identify the optimum cytokines
for therapy, and to delineate the most successful timing of
therapy (neoadjuvant intratumoral therapy versus adju-
vant vaccine therapy). We report here that the intrale-
sional injection of the combination of IL-12 and TNF-a
provides not only local control of the lesion, but generates
a potent systemic anti-tumor immune response. This
approach is superior to the use of a postoperative




Six- to eight-week-old female C57Bl6 mice were
purchased from The Jackson Laboratory (Bar Harbor,
NE) and maintained in specific pathogen-free conditions
at the Animal Maintenance Facility of the University of
MichiganMedical Center. B16-BL6 (B16) is a melanoma
cell line of spontaneous origin that has been studied
extensively [2]. MCA205 is a fibrosarcoma syngeneic to
C57Bl6 mice induced by 3-methylcholanthrene and was
used as a specificity control tumor [3]. Cell lines were
maintained in complete media consisting of RPMI 1640
supplemented with 10% heat-activated fetal bovine
serum, 0.1 mM non-essential amino acids, 1 mM sodium
pyruvate, 100 mg/ml streptomycin, 100 units/ml penicil-
lin, 50 mg/ml gentamycin and 0.5 mg/ml fungizone, all
from Life Technologies, Inc. (Grand Island, NY). In vivo
generation of tumors was accomplished by s.c. injection
of C57Bl6 mice with 2 105 viable B16 cells. Tumors
were measured every other day in two perpendicular
dimensions (a¼ length, b¼width) with a Vernier caliper,
and the size recorded as a volume (mm3) as calculated by
a*b2/2. Statistical significance between groups was calcu-
lated using an unpaired Students t-test, with a P-value
less than 0.05 considered statistically significant. Survival
curves were generated using SPSS statistical software,
version 13.0 (SPSS Inc., Chicago, IL). Statistical signi-
ficance for disease-free survival was calculated using
Log-Rank analysis with a P-value less than 0.05 consi-
dered statistically significant.
Microspheres
A phase inversion nanoencapsulation technique was
used for encapsulation of cytokines as described
previously. Briefly, BSA (Sigma Chemical Co., St. Louis,
MO), PLA {Mr 24,000 and Mr 2,000 (1:1, w/w):
Birmingham Polymers, Inc., Birmingham, AL}, and
recombinant cytokine in methylene chloride (Fisher,
Pittsburgh, PA) were rapidly poured into petroleum ether
(Fisher) for formation of microspheres. Microspheres
were filtered and lyophilized overnight for complete
removal of solvent. Four formulations containing 1%
BSA (w/w) were produced: (a) control (no cytokines);
(b) murine IL-12 {5 mg/mg of PLA} (R&D Systems,
Minneapolis, MN); (c) murine GM-CSF {5 mg/mg of
PLA} (Biosource Intl, Camarillo, CA); (d) murine TNF-a
{5 mg/mg of PLA} (R&D Systems).
Tumor-Draining LN Cells and Activation
At varying time points after inoculation, TDLN and
splenocytes were aseptically removed. Lymphoid cell
suspensions were prepared by mechanical dissociation
with 25-gauge needles and pressed with the blunt end of a
10-ml plastic syringe in RPMI 1640. The cells were
activated with 1 mg/ml anti-CD3 monoclonal antibody
(mAb) immobilized in 24-well plates (4 106 cells/2 ml/
well) for 2 days. The LN cells were subsequently cultured
in recombinant human IL-2 (Chiron Therapeutics,
Emeryville, CA) at 60 IU/ml IL-2 for 3 days at 2
105 cells/ml.
Splenocytes and Activation
Spleen cells obtained from the C57Bl6 mice were
treated with ammonium chloride-potassium lysis buffer
(0.83% ammonium chloride, 0.1% KHCO3 and 0.004%
EDTA) for 1 min to deplete erythrocytes and were
washed twice with HBSS. Splenocytes were then
activated with 1 mg/ml anti-CD3 mAb immobilized in
24-well plates (4 106 cells/2 ml/well) for 2 days. The
LN cells were subsequently cultured in 60 IU/ml IL-2 for
3 days at 2 105 cells/ml.
Measurement of In Vitro Cytokine Release
1 106 activated TDLN or splenocytes were co-
cultured with 1 106 B16 or MCA205 tumor cells
irradiated to 15,000 cGy in 2 ml of CM per well of a
24-well tissue culture plate. IL-2 (4 IU/ml) was added at
the beginning of the cultures, for 48 hr at 378C. The
supernatants were collected and, after centrifugation,
analyzed for interferon-g (IFNg) using commercially
Journal of Surgical Oncology DOI 10.1002/jso
404 Arora et al.
available ELISAs from PharMingen (San Diego, CA). A
standard curve starting at 1,000 U/ml was established and
11 serial twofold dilutions were performed. Experimental
values were computed with the use of regression analysis.
ELISPOT Assay
The number of IFN-g producing cells was measured
using ELISPOT assay after intratumoral injection of
cytokine-loaded PLAM. Briefly, 96-well plates were
coated with anti-mouse IFN-g antibody (PharMingen).
Activated splenocytes (1 106 cells/well) were cultured
for 48 hr at 378C in a 5% CO2 incubator alone or in the
presence of 4 105 irradiated B16 or MCA205 tumor
cells. After that time, wells were washed and incubated
overnight at 48C with a different clone of biotinylated
anti-IFN-g antibody (PharMingen). Reactions were visua-
lized and counted using anti-biotin-AP.
RESULTS
Treatment of Established Tumors With an Intratumoral
Injection of TNF-a Loaded PLAM Leads to
Complete Regression of B16 Melanoma
C57BL6 mice were inoculated subcutaneously with
B16 melanoma in the right flank. Treatment groups
comprised ten mice each. Six days after inoculation,
when all mice had palpable subcutaneous tumors, mice
were treated by a single intratumoral injection of
cytokine-loaded microspheres at a dose of 2 mg PLA/
tumor. Control mice were injected with a single injection
of BSA-loaded microspheres. Treatment groups con-
sisted of IL-12, GM-CSF or TNF-a either alone or in
combination. Mice treated with combination cytokines
were treated with 1 mg PLA/tumor for each cytokine.
Intratumoral injection of B16 tumors with PLAM loaded
with IL-12, GM-CSF or the combination caused
suppression of tumor growth, but did not lead to complete
tumor regression (Fig. 1). B16 tumors treated with TNF-
a, either alone or in combination with IL-12 or GM-CSF
resulted in statistically significant tumor regression.
Average tumor volume in mice treated with TNF-a
alone or in combination was 19.35 mm3 compared to
163.6 mm3 for mice treated with IL-12, GM-CSF or the
combination (P< 0.001 by Students t-test).
Treatment of Established Tumors With an Intralesional
Injection of Cytokine Loaded PLAM Induces
Tumor-Specific Pre-effector Cells Both
Regionally and Systemically
C57BL6 mice with B16 tumors treated by intratumoral
injection of PLAM loaded with IL-12, GM-CSF and
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Fig. 1. Tumor volume after intratumoral injection of cytokine-loaded PLAM on primary tumor growth. C57Bl6 mice (five mice per group) were
inoculated subcutaneously with 2 105 cells in the right flank. Palpable tumors were treated with a single intratumoral injection of poly-lactic-
acid microspheres encapsulating IL-12, TNF-a, and GM-CSF, alone or in combination. Tumors were measured in two perpendicular dimensions
(a¼ length, b¼width) and the size was recorded as a volume (mm3) as calculated by a*b/2. By Day 6 after therapy, intratumoral injection of B16
tumors with TNF-a loaded PLAM, either alone or in combination with IL-12 or GM-CSF, resulted in statistically significant tumor regression
(P< 0.001 by Students t-test).
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TNF-a, either alone or in combination, were sacrificed
7 days after treatment and tumor draining lymph nodes
(TDLN) and splenocytes were harvested for anti-CD3/
IL-2 activation. Lymphocytes were then co-cultured
either alone or in the presence of irradiated B16 cells
and serum IFN-g levels were determined by ELISA. As a
control for a tumor-specific response, activated lympho-
cytes were also co-cultured in the presence of MCA205,
a sarcoma cell line. A tumor specific response is
characterized as the difference in IFNg production
between cells co-cultured with B16 versus MCA205.
Intratumoral injection of IL-12 and TNF-a loaded
PLAM resulted in the greatest B16-specific response in
both the TDLN and splenocytes (Fig. 2). The ratio of the
specific to non-specific tumor response is demonstrated in
Figure 3.
To confirm these results, ELISPOT assay of the
splenocytes was performed to quantify tumor-specific
IFN-g producing cells. As with the IFN-g release assay,
splenocytes from mice treated intralesionally with IL-12
and TNF-a demonstrated the greatest increase in B16
specific T-cells, compared to either IL-12 alone, TNF-a
alone or GM-CSF alone or in combination. Mice treated
with IL-12 and TNF-a had 75/106 4.6 IFN-g producing
cells compared to 48.6/106 2.6 in the next highest
group; TNF-a and GM-CSF (P< 0.01). The results are
shown in Figure 4.
Intratumoral Injection of IL-12 and TNF-a Loaded
PLAM Prevents Re-Challenge After Treatment
In a separate experiment, C57BL6 mice were inocu-
lated subcutaneously with B16 melanoma in the right
flank. Ten days after inoculation, when all mice had
palpable subcutaneous tumors, mice were treated by a
single intratumoral injection of IL-12 and TNF-a loaded
microspheres either alone or in combination. Control
mice were treated with microspheres containing BSA.
Seven days after treatment, any residual tumor was
surgically excised. One week after surgery, all mice were
re-inoculated on the left flank with an identical
tumorigenic dose of B16. Six of seven mice treated with
BSA grew second tumors after treatment. As seen in
Figure 5, intratumoral injection of either IL-12 or TNF-a
alone did not prevent tumor growth when re-challenged.
However, mice treated by the combination of IL-12 and
TNF-a rejected tumors in 5 of 8 mice (Log Rank
w2¼ 4.111, P¼ 0.043).
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Fig. 2. Tumor specific IFN-g production by TDLN and splenocytes after intratumoral injection of cytokine-loaded PLAM. C57Bl6 mice (five
mice per group) with B16 tumors were treated with a single intratumoral injection of poly-lactic-acid microspheres encapsulating IL-12, TNF-a,
and GM-CSF alone or in combination. One week later, TDLN and spleens were removed aseptically. Lymphoid single-cell suspensions were
activated with anti-CD3 mAb and IL-2. Activated TDLN or splenocytes were cultured alone or with irradiated B16 or MCA205 tumor cells. The
supernatants were collected and analyzed for IFN-g production. Data are derived from two individual experiments (each experiment included
lymph nodes/spleens from 5 mice) (A) TDLN from mice treated with IL-12 and TNF-a PLAM initiated the greatest release of IFN-g in response
to B16 tumor cells and not to MCA205 cells. B: Splenocytes from mice with B16 tumor treated with PLAM loaded with the combination of IL-12
and TNF-a also showed the greatest response to B16 tumor cells but not MCA205 cells.
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Fig. 3. Ratio of specific to non-specific IFN-g production by TDLN and splenocytes after intratumoral injection of cytokine-loaded PLAM.
Fig. 4. IFN-g producing cells after intratumoral injection of cytokine-loaded PLAM as measured by ELISPOT assay. C57Bl6 mice (five mice
per group) with B16 tumors were treated with a single intratumoral injection of poly-lactic-acid microspheres encapsulating IL-12, TNF-a, and
GM-CSF alone or in combination. One week later, spleens were removed aseptically. Lymphoid single-cell suspensions were activated with
anti-CD3 mAb for 2 days and then cultured in 60 IU/ml IL-2 for 3 days. Activated splenocytes were co-cultured with irradiated B16 or MCA205
tumor cells. A: ELISPOT assay demonstrates that splenocytes from mice with B16 tumor treated with PLAM loaded with the combination of
IL-12 and TNF-a also showed the greatest number of tumor-specific T-cells. (P< 0.01 compared to each other group by t-test). B: Ratio of
specific to non-specific IFN-g production by splenocytes after intratumoral injection of cytokine-loaded PLAM.
Intratumoral Cytokine-Loaded Microspheres 407
Neoadjuvant Treatment of B16 Tumors With IL-12 and
TNF-a PLAM Leads to a Greater Systemic Anti-Tumor
Response Than an Adjuvant Vaccine
C57BL6 mice were inoculated subcutaneously with
B16 melanoma in the right flank. Eleven days after
inoculation, all mice with palpable subcutaneous tumors
underwent treatment. Mice in the neoadjuvant group
were treated with either intratumoral injection of IL-12 or
IL-12 and TNF-a loaded microspheres (2 mg PLAM/
mouse). Mice in the adjuvant group underwent surgical
resection. One week later, the mice who had neoadjuvant
treatment underwent surgical excision and the mice in the
adjuvant group received vaccination in the form of a
subcutaneous injection of 2 105 irradiated B16 cells in
combination with IL-12 or IL-12 and TNF-a loaded
microspheres. The dose of adjuvant cytokine was identi-
cal to the neoadjuvant group (2 mg PLAM/mouse). One
week later, all groups were sacrificed and TDLN and
splenocytes were harvested (Fig. 6). Mice treated with
neoadjuvant IL-12 and TNF-a had a significant, tumor-
specific response demonstrable in both the TDLN and the
splenocytes as compared to IL-12 alone in the neoadju-
vant setting. IL-12 and TNF-a PLAM as adjuvants to a
postoperative vaccine, however, failed to induce such a
response.
To rule out whether the radiation altered the ability of
the tumor cells to stimulate an immune response, naı̈ve
mice were vaccinated with live B16 cells in combination
with IL-12, TNF-a or IL-12 and TNF-a loaded micro-
spheres. Ten days after vaccination, TDLN and spleno-
cytes were harvested and an IFN-g release assay was
performed. IL-12 alone led to no increase in tumor-
specific response compared to non-stimulated lympho-
cytes in either the TDLN (171.07 18.6 vs. 177.2
20.3) or splenocytes (187.84 27.0 vs. 167.71 15.4).
TNF-a also had no significant effect. IL-12 and TNF-a
led to only a mild increase in IFNg production (360.21
27.9 vs. 270.34 33.3 in the TDLN, 345.43 35.0 vs.
284.09 37.7 in the splenocytes). Although the combi-
nation was superior to either cytokine alone, using live
B16 cells was no better than irradiated cells in generating
a significant tumor specific response in either the TDLN
or splenocytes.
Neoadjuvant Treatment of B16 Tumors With IL-12 and
TNF-a PLAM is Superior to an Adjuvant Cellular
Vaccine in Preventing Re-Challenge
C57BL6 mice were inoculated subcutaneously with
B16 melanoma in the right flank. Eleven days after
inoculation, all mice with palpable subcutaneous tumors
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Fig. 5. Disease-free survival after re-challenge following intratumoral injection of cytokine-loaded PLAM and surgical excision. Mice treated
by intratumoral injection of IL-12 and TNF-a loaded PLAM develop long-term immunity in comparison with the results of surgical excision
alone. C57BL6 mice were inoculated with a subcutaneous injection of 2 105 B16 cells in the right flank. When all mice had palpable
subcutaneous tumors, mice underwent injection with PLAM loaded with BSA controls, IL-12, TNF-a or IL-12 and TNF-a. Seven days later, the
residual tumor was resected and mice were then re-inoculated on the opposite flank with an identical tumorigenic dose of B16 cells. Treatment
with IL-12 or TNF-a alone failed to inhibit the growth of tumors. The combination of IL-12 and TNF-a, however, was able to significantly reduce
the growth of tumors after re-challenge. (Log Rank w2¼ 4.111, P¼ 0.043).
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underwent treatment. Mice in the neoadjuvant group
were treated with IL-12 and TNF-a loaded microspheres
(2 mg PLAM/mouse). Mice in the adjuvant group
underwent surgical resection. One week later, the mice
who had neoadjuvant treatment underwent surgical
excision and the mice in the adjuvant group received
vaccination in the form of a dorsal cervical subcutaneous
injection of 2 105 irradiated B16 cells in combination
with IL-12 and TNF-a loaded microspheres (2 mg
PLAM/mouse). One week later, all mice were re-
challenged with subcutaneous injection in the left flank
with a tumorigenic dose of B16 (2 105 cells), and
monitored for tumor growth. On Day 15 after re-
challenge, 2 of 9 (22%) mice treated with neoadjuvant
IL-12 and TNF-a loaded PLAM prior to surgical
resection developed tumors in the left flank, compared
to 7 of 8 mice (88%) treated with the adjuvant vaccine
(Log Rank w2¼ 4.594, P¼ 0.032; Fig. 7).
CONCLUSIONS
There has been significant interest in vaccination
strategies that aim to develop immune responses specific
to tumor-associated antigens, primarily the use of either
autologous whole-cell vaccines or dendritic cells pulsed
with autologous tumor lysate. The advantage of using
autologous tumor is exposure to the large repertoire of
tumor-associated antigens specific to the patient. The
immunostimulatory effects of cytokines can be used to
further improve the efficacy of these vaccines by
recruiting and activating APC to the vaccination site,
increasing the uploading and presentation of tumor
antigens, and escalating the differentiation and prolifera-
tion of effector cells. As higher cytokine levels can be
sustained at the site by local production, without the
toxicity associated with systemic administration, auto-
logous cellular vaccines and dendritic cells can be
genetically modified with the gene of the cytokine of
interest.
While cytokine gene-modified cellular and dendritic
cell vaccines show the most potential from an immuno-
logic standpoint, they are greatly hampered clinically by
the availability of sufficient tumor. Patients with adequate
harvestable tumor (those with bulky lymph node
metastases or multiple metastatic foci), while possessing
enough tumor to create a vaccine, have the worst
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Fig. 6. Tumor-specific IFN-g production by TDLN and splenocytes after either neoadjuvant intratumoral treatment or postoperative autologous
vaccination. C57Bl6 mice were inoculated with B16 melanoma and treated by one of two methods once subcutaneous tumors were present. Mice
in the neoadjuvant group were treated with either intratumoral injection of IL-12 or IL-12 and TNF-a loaded microspheres (2 mg PLAM/mouse).
Mice in the adjuvant group underwent surgical resection. One week later, the mice who had neoadjuvant treatment underwent surgical excision
and the mice in the adjuvant group received vaccination in the form of a subcutaneous injection of 2 105 irradiated B16 cells in combination
with IL-12 or IL-12 and TNF-a loaded microspheres (at an identical dose to the neoadjuvant group). One week later, TDLN and spleens were
removed aseptically. Lymphoid single-cell suspensions were activated with anti-CD3 mAb for 2 days and then cultured in 60 IU/ml IL-2 for
3 days. Activated TDLN (Fig. 5A) or splenocytes (Fig. 5B) were co-cultured with irradiated B16 or MCA tumor cells. The supernatants were
collected and analyzed for IFN-g production. Only IL-12 and TNF-a in the neoadjuvant setting was able to generate a significant tumor-specific
response (P< 0.01 compared to each other group by Students t-test).
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prognosis and are least likely to respond to therapy.
Immunotherapy is most likely to be effective in the
adjuvant setting, but these patients rarely have an
extremely limited availability of tumor. Therefore, new
approaches to immunotherapy are needed, those that
utilize autologous whole cells but do not require ex vivo
manipulation. One such approach is in situ vaccination,
which consists of delivering cytokines directly to the site
of the tumor [4–11]. In this way, the tumor itself serves as
the vaccine, precluding the cost and difficulty in
establishing a cell line and transfecting it with the gene
for a cytokine. We have previously described an alternate
strategy for in situ cytokine delivery: the use of slow-
release polymer microspheres [1,12,13]. Using the poorly
immunogenic B16 (murine melanoma) model, we sought
to identify the optimum cytokines (or combination) for in
situ vaccination, and to compare this neoadjuvant
approach to the adjuvant use of autologous cellular
vaccines.
The result confirms the synergistic effects of intratu-
moral IL-12 and TNF-a in generating a systemic anti-
tumor response. In this model, neither cytokine alone nor
GM-CSF alone or their combination was effective. IL-12
exerts potent Th1-inducing effects and augments NK cell
cytotoxicity [15,16]. IL-12 activates and mobilizes
tumor-alerted NK and T-cells in lymphoid organs, and
seems to exert its greatest effect in those sites where T-
lymphocytes have been activated and have accumulated
[17,18]. Against a poorly immunogenic tumor such as
B16 melanoma, intratumoral IL-12 alone may not be able
to stimulate enough inflammation and tumor necrosis to
initiate the activation of T-cells. Combining IL-12 with
other agents may therefore enhance its anti-tumor
efficacy. Previous reports have demonstrated increased
activity when IL-12 is combined with GM-CSF [19], IL-
18 [6,20], and IL-2 [10,21]. TNF-a is a multipotent
cytokine that causes hemorrhagic necrosis in tumors,
evokes apoptosis and activates immune cells [22]. As
with IL-12, while some tumor cell lines are killed by
TNF-a alone, others are not at all affected, and require
the combination of TNF-a with other cytokines [23]. Our
results confirm that the combination of IL-12 and TNF-a
appears to be a particularly effective combination.
Synergistic effects possibly include skewing towards a
Th1 response [24], induction of the tumoricidal activity
of macrophages [25], and increased necrosis and tumor
infiltration of both PMN and CD8þ cells at the site of the
tumor [13].
Given the synergy seen between IL-12 and TNF-a, we
sought to examine whether the cytokines are better used
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Fig. 7. Disease-free survival after re-challenge following intratumoral injection of cytokine-loaded PLAM and surgical excision. C57Bl6 mice
were inoculated with B16 melanoma (five mice per group) and treated by one of two methods once subcutaneous tumors were present. Mice in the
neoadjuvant group (- - - - -) were treated with either intratumoral injection of IL-12 and TNF-a loaded microspheres (2 mg PLAM/mouse). Mice
in the adjuvant group initially underwent surgical resection (———). One week later, the mice who had neoadjuvant treatment underwent surgical
excision and the mice in the adjuvant group received vaccination in the form of a subcutaneous injection of 2 105 irradiated B16 cells in
combination with IL-12 and TNF-a loaded microspheres (at an identical dose to the neoadjuvant group). One week after this, mice were
re-inoculated on the opposite flank with an identical tumorigenic dose of B16 cells. A postoperative autologous cellular vaccine, using IL-12 and
TNF-a as adjuvant, failed to inhibit the growth of tumors. When delivered prior to surgical resection, however, this resulted in a significant
resistance to re-challenge (Log rank w2¼ 4.594, P¼ 0.032).
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intratumorally as opposed to adjuvants to postoperative
vaccines. The use of intratumoral therapy would shift
the timing of immunotherapy from postoperative to pre-
operative. These results clearly demonstrate that neoad-
juvant therapy is superior to adjuvant therapy in both
stimulating an anti-tumor T-cell response and preventing
tumor growth when re-challenged. Postoperative vac-
cines are limited by both the amount of tumor (and
tumor-associated antigens) available for uptake and the
need to irradiate the tumor cells, which has been shown to
induce less of an immune response, perhaps contributing
to the ineffectiveness of postoperative vaccines [26].
However, using live tumor cells for vaccination in
combination with IL-12 and TNF-a, failed to generate
results similar to intratumoral therapy, suggesting that the
irradiation was not the reason why the vaccine failed.
This makes a strong argument that in situ vaccination
may be a better immunologic approach than postopera-
tive vaccination. In addition, there are other potential
advantages to the neoadjuvant approach. In situ vaccina-
tion precludes the need to harvest adequate amounts of
tumor or manipulate these cells ex vivo, which is not only
time consuming and cost-prohibitive, but not technically
feasible for many solid tumors. Chemotherapy given
prior to surgical resection of a solid tumor can offer an
increased likelihood of complete resection and may
increase the odds of cure by reducing or eliminating
micrometastatic disease at an earlier time point. This
same premise may be applied to immunotherapy as well.
In conclusion, intratumoral IL-12 and TNF-a loaded
PLAMs results in not only tumor ablation, but also in the
generation of a regional and systemic tumor-specific
immune response capable of preventing re-challenge and
improving disease-free survival after resection. The local
and sustained release of these cytokines in the neoadju-
vant setting is greatly superior to their use as an adjuvant
to a postoperative autologous cellular vaccine. Based on
these results, we are now examining the mechanisms
behind the apparent synergistic effects between IL-12 and
TNF-a at both the site of injection in the primary tumor
and on established metastatic disease. This information
will hopefully further guide the clinical applicability of
these cytokines in the neoadjuvant setting and suggest
additional methods to augment the resultant anti-tumor
immune response. Furthermore, these results suggest
there may be a clinical benefit to shifting away from
postoperative adjuvant immunotherapy towards preo-
perative intratumoral immunotherapy.
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